Literature DB >> 29300112

Zoledronic acid overcomes chemoresistance by sensitizing cancer stem cells to apoptosis.

H Rouhrazi1, N Turgan2, G Oktem3,4.   

Abstract

Unlike low tumorigenic bulk tumor cells (non-CSCs), cancer stem cells (CSCs) are a subset of tumor cells that can self-renew and differentiate into different cancer subtypes. CSCs are considered responsible for tumor recurrence, distant metastasis, angiogenesis, and drug or radiation resistance. CSCs also are resistant to apoptosis. Zoledronic acid (ZA) is a third generation bisphosphonate that reduces cell proliferation and exhibits anti-tumor effects by inducing cell death in some malignancies; however, the effects of ZA on CSCs are unclear. We investigated the anti-cancer effects of ZA on two epithelial cancer cell lines, prostate DU-145 and breast MCF7, focusing primarily on induction and activation of apoptosis. Cluster of differentiation (CD) 133+/CD44+ prostate CSCs and CD 44+/CD24 breast CSCs were isolated from the DU-145 human prostate cancer and MCF-7 human breast cancer cell lines, respectively, using FACSAria flow cytometry cell sorting. CSCs and non-CSCs were exposed to increasing concentrations of ZA for 24, 48 and 72 h to determine the IC50 dose. Annexin-V assay for detecting cell death and cell cycle was performed using the Muse™ Cell Analyzer. Prostate CSCs and non-CSCs were assayed by quantitative reverse transcription PCR (qRT-PCR) array for detecting 84 key apoptosis related genes. Gene regulation at the protein level was investigated by immunofluorescence. ZA caused a dose- and time-dependent decrease in cell viability. Treatment with ZA resulted in a concomitant increase in apoptosis and cell cycle arrest at S-phase in CSCs. Significant over/under-expressions were detected in seven of the genes of ZA-treated DU-145 CSCs cells. Expressions of CASP9, CASP4, BAX and BAD genes increased, while the expressions of BIRC3, BIRC2 and BCL2 genes decreased. In the DU-145 non-CSCs, five genes exhibited changes in gene expression after ZA treatment, two exhibited increased expression (CASP7 and BAD) and three exhibited decreased expression (BIRC3, BIRC2 and BCL2). ZA caused cell death of drug resistant breast MCF-7 and prostate DU-145 cancer stem cells by activating apoptosis. ZA can facilitate the intrinsic pathway of apoptosis in human prostate CSCs by down-regulating anti-apoptotic genes and up-regulating pro-apoptotic genes. ZA may be an effective therapeutic agent for targeting chemoresistance in CSCs.

Entities:  

Keywords:  apoptosis; bisphosphonates; cancer; drug resistance; stem cells; zoledronic acid

Mesh:

Substances:

Year:  2018        PMID: 29300112     DOI: 10.1080/10520295.2017.1387286

Source DB:  PubMed          Journal:  Biotech Histochem        ISSN: 1052-0295            Impact factor:   1.718


  4 in total

1.  Sonic hedgehog signaling is associated with resistance to zoledronic acid in CD133high/CD44high prostate cancer stem cells.

Authors:  Eda Acikgoz; Gunel Mukhtarova; Araz Alpay; Cigir Biray Avci; Bakiye Goker Bagca; Gulperi Oktem
Journal:  Mol Biol Rep       Date:  2021-05-04       Impact factor: 2.316

2.  Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression.

Authors:  Giorgia Centonze; Dora Natalini; Alessio Piccolantonio; Vincenzo Salemme; Alessandro Morellato; Pietro Arina; Chiara Riganti; Paola Defilippi
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

3.  Carbon-Ion Beam Irradiation Alone or in Combination with Zoledronic acid Effectively Kills Osteosarcoma Cells.

Authors:  Eun Ho Kim; Mi-Sook Kim; Akihisa Takahashi; Masao Suzuki; Guillaume Vares; Akiko Uzawa; Akira Fujimori; Tatsuya Ohno; Sei Sai
Journal:  Cancers (Basel)       Date:  2020-03-16       Impact factor: 6.639

4.  Inhibition of lncRNA KCNQ1OT1 Improves Apoptosis and Chemotherapy Drug Response in Small Cell Lung Cancer by TGF-β1 Mediated Epithelial-to-Mesenchymal Transition.

Authors:  Deyu Li; Qin Tong; Yuane Lian; Zhizhong Chen; Yaru Zhu; Weimei Huang; Yang Wen; Qiongyao Wang; Shumei Liang; Man Li; Jianjing Zheng; Zhenhua Liu; Huanxin Liu; Linlang Guo
Journal:  Cancer Res Treat       Date:  2021-03-09       Impact factor: 4.679

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.